

# Yash B Joshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12031781/publications.pdf>

Version: 2024-02-01

49  
papers

1,415  
citations

304743

22  
h-index

361022

35  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1988  
citing authors

#	ARTICLE	IF	CITATIONS
1	The viability of the frequency following response characteristics for use as biomarkers of cognitive therapeutics in schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 372-382.	2.0	7
2	Click-evoked auditory brainstem responses (ABRs) are intact in schizophrenia and not sensitive to cognitive training. <i>Biomarkers in Neuropsychiatry</i> , 2022, 6, 100046.	1.0	2
3	Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 373-385.	4.3	46
4	Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 280-287.	2.0	25
5	Source decomposition of the frontocentral auditory steady-state gamma band response in schizophrenia patients and healthy subjects. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 172-179.	1.8	10
6	Sources of the frontocentral mismatch negativity and P3a responses in schizophrenia patients and healthy comparison subjects. <i>International Journal of Psychophysiology</i> , 2021, 161, 76-85.	1.0	6
7	Neural network dynamics underlying gamma synchronization deficits in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110224.	4.8	17
8	Abnormal phase discontinuity of alpha- and theta-frequency oscillations in schizophrenia. <i>Schizophrenia Research</i> , 2021, 231, 73-81.	2.0	8
9	Anticholinergic Medication Burden Associated Cognitive Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2021, 178, 838-847.	7.2	80
10	Central auditory processing deficits in schizophrenia: Effects of auditory-based cognitive training. <i>Schizophrenia Research</i> , 2021, 236, 135-141.	2.0	9
11	Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1431-1438.	2.6	3
12	Evaluation of the frequency following response as a predictive biomarker of response to cognitive training in schizophrenia. <i>Psychiatry Research</i> , 2021, 305, 114239.	3.3	4
13	Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients. <i>Schizophrenia Research</i> , 2020, 215, 97-104.	2.0	13
14	Abnormal Spontaneous Gamma Power Is Associated With Verbal Learning and Memory Dysfunction in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 832.	2.6	31
15	Memantine effects on auditory discrimination and training in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 2180-2188.	5.4	20
16	Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia. <i>Translational Psychiatry</i> , 2020, 10, 405.	4.8	35
17	A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients. <i>Neuropsychopharmacology</i> , 2020, 45, 2198-2206.	5.4	29
18	Neurophysiologic Characterization of Resting State Connectivity Abnormalities in Schizophrenia Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 608154.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Abnormal Effective Connectivity Underlying Auditory Mismatch Negativity Impairments in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 1028-1039.	1.5	11
20	Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 562-568.	1.5	57
21	Neurophysiological biomarkers for schizophrenia therapeutics. <i>Biomarkers in Neuropsychiatry</i> , 2020, 2, 100012.	1.0	18
22	Auditory-Based Cognitive Training Drives Short- and Long-Term Plasticity in Cortical Networks in Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
23	Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia. <i>Schizophrenia Research</i> , 2019, 210, 215-220.	2.0	8
24	Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients. <i>Schizophrenia Research</i> , 2019, 208, 384-389.	2.0	21
25	Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 606-612.	5.4	47
26	Mismatch negativity impairment is associated with deficits in identifying real-world environmental sounds in schizophrenia. <i>Schizophrenia Research</i> , 2018, 191, 5-9.	2.0	22
27	Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 554.	2.6	13
28	Computerized cognitive training is associated with improved psychosocial treatment engagement in schizophrenia. <i>Schizophrenia Research</i> , 2018, 202, 341-346.	2.0	13
29	Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care. <i>Schizophrenia Research</i> , 2018, 202, 378-384.	2.0	36
30	Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2017, 42, 2633-2639.	5.4	55
31	Dissociative Intoxication and Prolonged Withdrawal Associated With Phenibut. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 478-480.	1.4	20
32	The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 181-186.	8.7	69
33	Gamma Secretase-Activating Protein Is a Substrate for Caspase-3: Implications for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 720-728.	1.3	34
34	Lipid Peroxidation in Psychiatric Illness: Overview of Clinical Evidence. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-5.	4.0	44
35	Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6894-6902.	2.9	26
36	Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. <i>Neurobiology of Aging</i> , 2014, 35, 1813-1820.	3.1	165

#	ARTICLE	IF	CITATIONS
37	Overexpression of 12/15-lipoxygenase increases anxiety behavior in female mice. <i>Neurobiology of Aging</i> , 2014, 35, 1032-1036.	3.1	6
38	Novel lipid signaling pathways in Alzheimer's disease pathogenesis. <i>Biochemical Pharmacology</i> , 2014, 88, 560-564.	4.4	33
39	Modulation of lipopolysaccharide-induced memory insult, $\beta$ -secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase. <i>Neurobiology of Aging</i> , 2014, 35, 1024-1031.	3.1	26
40	04â€09â€01: SLEEP DEPRIVATION IMPAIRS MEMORY, TAU METABOLISM, AND SYNAPTIC INTEGRITY OF A MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2014, 10, P268.	0.8	1
41	The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 436.	3.7	60
42	The 12â€15â€lipoxygenase is a modulator of Alzheimer's-related tau pathology <i>in vivo</i> . <i>Aging Cell</i> , 2013, 12, 1082-1090.	6.7	37
43	The involvement of 5-lipoxygenase activating protein in anxiety-like behavior. <i>Journal of Psychiatric Research</i> , 2013, 47, 694-698.	3.1	16
44	Knockout of 5â€lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. <i>Aging Cell</i> , 2013, 12, 706-711.	6.7	19
45	5-Lipoxygenase Activating Protein Reduction Ameliorates Cognitive Deficit, Synaptic Dysfunction, and Neuropathology in a Mouse Model of Alzheimer's Disease. <i>Biological Psychiatry</i> , 2013, 74, 348-356.	1.3	40
46	Modulation of Amyloid- $\beta$ Production by Leukotriene B4 via the $\beta$ -Secretase Pathway. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 503-506.	2.6	14
47	Stress Hormone Leads to Memory Deficits and Altered Tau Phosphorylation in a Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 167-176.	2.6	55
48	Vitamin E in aging, dementia, and Alzheimer's disease. <i>BioFactors</i> , 2012, 38, 90-97.	5.4	73
49	Knockout of 5-Lipoxygenase Results in Age-Dependent Anxiety-Like Behavior in Female Mice. <i>PLoS ONE</i> , 2011, 6, e29448.	2.5	16